Company Overview and News

0
Petronet LNG Limited - Analysts/Institutional Investor Meet/Con. Call Updates

18h nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
PQRTY PETRONET 532522

0
Wary of high gas prices, Essar to go slow on plan to build LNG terminals

23h livemint
Mumbai: With natural gas prices shooting up globally, Essar Ports is going slow on its plans to build liquefied natural gas terminals at the Hazira port in Gujarat, chief executive officer Rajiv Agarwal told Mint.
IOC PQRTY 530965 PETRONET 532522

0
Petronet LNG Limited - Updates

2018-07-16 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
PQRTY PETRONET 532522

0
Petronet LNG gains 1.5% after Deutsche Bank maintains buy; sets target at Rs 310

2018-07-10 moneycontrol
Shares of Petronet LNG gained over 1.5 percent intraday on Tuesday as Deutsche Bank maintained a buy call on the stock with a target of Rs 310.
DB PQRTY PETRONET 532522

3
GSPC to commission Mundra LNG terminal in 2-3 months

2018-07-08 livemint
New Delhi: Gujarat State Petroleum Corp. Ltd will commission a 5 MTPA LNG import terminal at Mundra in the next 2-3 months, GSPC managing director Jagdip Narayan Singh said Sunday. Mundra will be third terminal is Gujarat to import supercooled natural gas, or liquified natural gas (LNG) in cryogenic ships. This LNG will then be converted into gaseous state and transported by pipelines to consumers.
IOC 500325 ANNRY ADANIENT RELIANCE PQRTY BP GSPL 532702 530965 PETRONET 512599 BP.A BP.B 532522 BP RIGD BPAQF RLNIY

0
Natural gas, jet fuel may come under GST ambit, which companies will benefit?

2018-07-04 moneycontrol
With the Goods & Services Tax completing 1 year since its rollout, the GST Council is now considering bringing natural gas and aviation turbine fuel (ATF) under the tax ambit on an experimental basis.
PQRTY PETRONET 532522

0
ONGC gets nod to explore rejig options

2018-07-03 freepressjournal.in
New Delhi : The board of state-owned Oil and Natural Gas Corp (ONGC) has given in-principle approval for exploring options for a restructuring of the group firms including the merger of subsidiaries MRPL and HPCL.
PQRTY HINDPETRO 500104 PETRONET 532522

0
ONGC board gives nod to explore group restructuring options

2018-07-02 livemint
New Delhi: The board of state-owned Oil and Natural Gas Corp (ONGC) has given in-principle approval for exploring options for a restructuring of the group firms including the merger of subsidiaries MRPL and HPCL.
PQRTY PETRONET 532522

0
Petronet LNG Limited - Updates

2018-06-29 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
PQRTY PETRONET 532522

10
ICICI Bank up nearly 2% as board appoints Girish Chaturvedi non-executive part-time Chairman

2018-06-29 moneycontrol
ICICI Bank share price gained 1.7 percent intraday on Friday after the board appointed Girish Chandra Chaturvedi as non-executive part-time Chairman.
ICICIBANK 500116 532483 532174 IBN IDBI PQRTY PETRONET CANBK 532522 CNRYY

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

22h - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

23h - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...